A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer.

dc.contributor.advisor

Wang, Xiao-Fan

dc.contributor.advisor

Blobe, Gerard C

dc.contributor.advisor

Kirsch, David G

dc.contributor.advisor

Mathey-Prevot, Bernard

dc.contributor.advisor

Yan, Hai

dc.contributor.author

Curtis, Valerie Forbes

dc.date.accessioned

2012-01-10T15:58:21Z

dc.date.issued

2011

dc.department

Molecular Cancer Biology

dc.description.abstract

In many cancer types, infiltration of bone marrow-derived myeloid cells in the tumor microenvironment is often associated with enhanced angiogenesis and tumor progression, resulting in poor prognosis. The polypeptide chemokine PK2 (Bv8) regulates myeloid cell mobilization from the bone marrow, leading to activation of angiogenesis as well as accumulation of macrophages and neutrophils in the tumor site. Neutralizing antibodies against PK2 display potent anti-tumor efficacy, illustrating the potential of PK2-antagonists as therapeutic agents for the treatment of cancer. However, antibody-based therapies can be too large to treat certain diseases and too expensive to manufacture while small molecule therapeutics are not prohibitive in these ways. In this study, we demonstrate the anti-tumor activity of a small molecule PK2 antagonist, PKRA7, in the contexts of glioblastoma and pancreatic cancer xenograft tumor models. In the highly vascularized glioblastoma, PKRA7 decreased blood vessel density while increasing necrotic areas in the tumor mass. Consistent with the anti-angiogenic activity of PKRA7 in vivo, this compound effectively reduced PK2-induced microvascular endothelial cell branching in vitro. For the poorly vascularized pancreatic cancer, the primary anti-tumor effect of PKRA7 is mediated by the blockage of myeloid cell migration and infiltration. At the molecular level, PKRA7 inhibits PK2-induced expression of several pro-migratory chemokines and chemokine receptors in macrophages. Combining PKRA7 treatment with standard chemotherapeutic agents resulted in enhanced effects in xenograft models for both glioblastoma and pancreatic tumors. Taken together, our results indicate that the anti-tumor activity of PKRA7 can be mediated by distinct mechanisms that are relevant to the pathological features of the specific type of cancer. This small molecule PK2 antagonist holds the promise to be further developed as an effective agent for combinational cancer therapy.

dc.identifier.uri

https://hdl.handle.net/10161/4982

dc.language

eng

dc.language.iso

en_US

dc.subject

Animals

dc.subject

Antineoplastic Agents

dc.subject

Carrier Proteins

dc.subject

Cell Line, Tumor

dc.subject

Cell Movement

dc.subject

Cell Transformation, Neoplastic

dc.subject

Endothelial cells

dc.subject

Gastrointestinal Hormones

dc.subject

Glioma

dc.subject

Humans

dc.subject

Macrophages

dc.subject

Mice

dc.subject

Myeloid Cells

dc.subject

Neovascularization, Pathologic

dc.subject

Nerve Tissue Proteins

dc.subject

Neuropeptides

dc.subject

Pancreatic Neoplasms

dc.subject

Receptors, N-Methyl-D-Aspartate

dc.subject

Tumor Burden

dc.subject

Tumor microenvironment

dc.subject

Xenograft Model Antitumor Assays

dc.title

A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer.

dc.type

Dissertation

duke.embargo.months

24

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/23372791

pubs.organisational-group

Duke

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Pharmacology & Cancer Biology

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Pathology

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Duke Cancer Institute

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Curtis_duke_0066D_11134.pdf
Size:
1.97 MB
Format:
Adobe Portable Document Format

Collections